Credit Suisse Group set a $156.00 price target on Johnson & Johnson (NYSE:JNJ) in a research report report published on Tuesday, AnalystRatings.com reports. The brokerage currently has a buy rating on the stock.

Several other brokerages have also recently issued reports on JNJ. Bank of America reissued a hold rating and set a $150.00 price target on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Wells Fargo & Co reissued an outperform rating and set a $157.00 price target (up previously from $152.00) on shares of Johnson & Johnson in a research report on Monday, May 6th. Zacks Investment Research cut shares of Johnson & Johnson from a buy rating to a hold rating and set a $139.00 price target on the stock. in a research report on Thursday, July 18th. Goldman Sachs Group began coverage on shares of Johnson & Johnson in a research report on Tuesday, May 28th. They set a buy rating on the stock. Finally, Raymond James reduced their price target on shares of Johnson & Johnson from $147.00 to $146.00 and set an outperform rating on the stock in a research report on Wednesday, July 17th. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $150.60.

Shares of JNJ stock opened at $128.36 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. The firm has a market cap of $342.14 billion, a PE ratio of 15.69, a price-to-earnings-growth ratio of 2.19 and a beta of 0.69. The company has a 50-day moving average of $130.89 and a two-hundred day moving average of $136.37. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. The company had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. Johnson & Johnson’s revenue was down 1.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.10 earnings per share. Sell-side analysts anticipate that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, August 26th. This represents a $3.80 annualized dividend and a dividend yield of 2.96%. Johnson & Johnson’s dividend payout ratio is presently 46.45%.

In other news, Director Marillyn A. Hewson bought 3,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, June 11th. The shares were purchased at an average price of $139.68 per share, with a total value of $419,040.00. Following the completion of the acquisition, the director now directly owns 3,000 shares in the company, valued at $419,040. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.23% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of JNJ. Virtus ETF Advisers LLC acquired a new stake in Johnson & Johnson during the second quarter worth approximately $25,000. Krane Funds Advisors LLC acquired a new stake in Johnson & Johnson during the second quarter worth approximately $26,000. Crewe Advisors LLC raised its holdings in Johnson & Johnson by 725.9% during the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after purchasing an additional 196 shares in the last quarter. Evolution Wealth Advisors LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $40,000. Finally, Permanens Capital L.P. raised its holdings in Johnson & Johnson by 50.0% during the second quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after purchasing an additional 100 shares in the last quarter. 67.23% of the stock is currently owned by hedge funds and other institutional investors.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Understanding Analyst Ratings

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.